CellWell record HH-408647
Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6
Harpreet S Bajaj; Liana K Billings; Palash Sharma; Joshua A Levine; Angel Rodriguez; Hiren Patel
2026
In plain language
Pooled analysis of SURPASS-5 and -6 found tirzepatide added to basal insulin glargine was associated with reduced HbA1c, fasting glucose and insulin dose across age, HbA1c, diabetes duration and insulin dose subgroups, with low hypoglycemia.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-408647
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.